Clinical trials: Attention Deficit Hyperactivity Disorder, completed
Attention Deficit Disorder With Hyperactivity
Screening for Attention-deficit/Hyperactivity Disorder (ADHD) in Adolescent and Adult High Risk Populations
This study aims to investigate the prevalence of ADHD and other psychopathology, and current function and life quality among several high risk populations of imprisoned adults and adolescents who receive special resources in…
- Trial name
- NCT00745524
- Where
- 2 sites in Taiwan
- Volunteers
- 1,910 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
ADHD, Smoking
Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta
The researchers will study 100 families over three years, each with a child (proband) between the ages of 12-17, with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of ADHD.
- Trial name
- NCT00181792
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
- Trial name
- NCT00564954
- Testing
- Dex-methylphenidate hydrochloride extended-release (Focalin XR)
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
ADHD
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate efficacy, safety and tolerability of metadoxine (MG01CI) extended release formulation for the treatment of adults diagnosed with ADHD
- Trial name
- NCT01243242
- Testing
- Metadoxine (MG01CI)
- Where
- 2 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Alcobra Ltd.
Attention Deficit Hyperactivity Disorder
Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Children with Attention Deficit Hyperactivity Disorder (ADHD) have numerous areas of neuropsychological dysfunction including response inhibition, working memory, and attention.
- Trial name
- NCT01238822
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)
This study will test the efficacy of a systematic, multi-modal intervention protocol designed to improve sleep functioning and subsequent alleviation of daytime cognitive and behavioral difficulties among children diagnosed with…
- Trial name
- NCT00867451
- Testing
- Sleep Intervention, Melatonin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Disorder With Hyperactivity
CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the…
- Trial name
- NCT00246207
- Testing
- CONCERTA (OROS methylphenidate hydrochloride)
- Volunteers
- 32 people
- Sponsor
- Janssen-Ortho Inc., Canada
Attention Deficit Hyperactivity Disorder
Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory
This study investigates whether OROS-methylphenidate improves performance on different aspects of attention and memory in children with Attention-Deficit Hyperactivity Disorder (ADHD).
- Trial name
- CHOP (NCT00530257)
- Testing
- OROS-methylphenidate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Autism Spectrum Disorder
Autism Spectrum Disorders (ASD) Driving Study
The proposed pilot study will begin to assess whether driving impairments are included in the functional deficits associated with Autism Spectrum Disorders (ASDs).
- Trial name
- NCT01263756
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
ADHD
The Reinforcing Mechanisms of Smoking in Adult ADHD
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated.
- Trial name
- NCT00573859
- Testing
- ADHD medication
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Attention Deficit Hyperactivity Disorder
A Bioequivalence (BE) Study in Healthy Subjects
To demonstrate the bioequivalence of 12.5 milliliters (mL) of atomoxetine oral solution (4 milligrams per milliliter [mg/mL]) compared with 2 capsules of atomoxetine (25 mg per capsule) in healthy adult male Japanese subjects.
- Trial name
- NCT01177943
- Testing
- Atomoxetine
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
- Trial name
- NCT00391729
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abbott
Attention Deficit Disorder With Hyperactivity, Methylphenidate
Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)
The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Methylphenidate, Pharmacogenetics
- Trial name
- NETADHD (NCT00757029)
- Testing
- norepinephrine transporter polymorphism,
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Hallym University Medical Center
Attention Deficit Hyperactivity Disorder
Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies
Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to…
- Trial name
- TEAMS (NCT01073176)
- Testing
- TEAMS (Training Attention Executive and Motor Skills)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Queens College, The City University of New York
ADHD
Nicotine and Behavior in Adult ADHD
Attention deficit hyperactivity disorder (ADHD) is characterized by inattention, impulsivity, and hyperactivity that are frequently treated with stimulant medications such as Ritalin. Many people with ADHD smoke.
- Trial name
- NCT00573248
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of California, Irvine
Adult ADHD
Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
- Trial name
- NCT01012375
- Testing
- AZD1446
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- AstraZeneca
Attention Deficit Hyperactivity Disorder
Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)
Children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who are not tolerating or not responding well to stimulant therapy will be included in this study.
- Trial name
- ADHD SWITCH (NCT00760747)
- Testing
- Atomoxetine
- Where
- 6 sites in Australia, Mexico and 1 more
- Volunteers
- 112 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a parallel design, double-blind, placebo-controlled, multi-center, 38-week treatment trial of atomoxetine in adults with attention deficit hyperactivity disorder (ADHD) who are currently living in a family situation with…
- Trial name
- NCT00190775
- Testing
- Atomoxetine Hydrochloride
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Eli Lilly and Company
ADHD
Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder
Using a virtual reality program in screening and treatment of ADHD.
- Trial name
- NCT00364702
- Testing
- methylphenidate
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center